Effect of throat exercises in lower jaw advancement to treat sleep apnea

ISRCTN ISRCTN13128082
DOI https://doi.org/10.1186/ISRCTN13128082
Secondary identifying numbers AWAGAP-2023-1
Submission date
14/04/2023
Registration date
17/04/2023
Last edited
09/05/2025
Recruitment status
Recruiting
Overall study status
Ongoing
Condition category
Nervous System Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Obstructive sleep apnoea/hypopnoea syndrome (OSAHS) is a condition in which the upper airway is narrowed or closes during sleep when muscles relax, causing under-breathing or stopping breathing. Myofunctional therapy (MT) is a treatment option for OSAHS based on performing regular exercises with the upper airway muscles in order to increase their tone of them and prevent their collapsibility. Mandibular advancement devices (MADs) are used for OSAHS treatment creating a tongue and jaw protrusion and causing changes in the upper airway (UA) widening its dimensions. The aim of this study is to determine the effectiveness of and adherence to upper airway muscle exercises performed with an App (Airway Gym) in patients with moderate OSAHS who use a MAD.

Who can participate?
Patients aged between 18 and 75 years with moderate OSA

What does the study involve?
Participants are randomly allocated to one of four groups. One group will undergo sham therapy. Another group will have to use an app to perform myofunctional exercises and another will do exercises with a MAD and another will have to wear a MAD for OSA treatment for 3 months. Patients will be examined and the tone of the upper airway muscles is measured with a tongue digital spoon device. Polysomnography (sleep study) will be repeated after 3 months in all the groups. A sleep diary will be provided to patients to measure adherence.

What are the possible benefits and risks of participating?
The benefits will come from improvements in OSAHS symptoms. The researchers hope no risks will be involved.

Where is the study run from?
Grupo Quironsalud (Spain)

When is the study starting and how long is it expected to run for?
January 2023 to March 2026

Who is funding the study?
Investigator initiated and funded

Who is the main contact?
Dr Carlos O'Connor-Reina, carlos.oconnor@quironsalud.es

Contact information

Dr Carlos O´Connor-Reina
Principal Investigator

Avda menendez y Pelayo 44 5c
Sevilla
41003
Spain

ORCiD logoORCID ID 0000-0002-1670-4235
Phone +34 (0)952780540
Email carlos.oconnor@quironsalud.es

Study information

Study designProspective controlled randomized clinical trial pilot study
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet 43496_PIS.pdf
Scientific titleInfluence of oropharyngeal exercises in the adherence and efficacy of mandibular advancement device therapy in patients with moderate obstructive sleep apnea: a multicentre randomized clinical trial pilot study
Study acronymMADOMTCOMPLIANCE
Study objectivesThe main objective will be to evaluate the changes in apnea-hypopnea index (AHI), oxygen desaturation index (ODI) and minimal O2 desaturation (min sat o2) after 3 months of myofunctional therapy (MT) with an App in moderate sleep apnoea patients that use a mandibular advancement device (MAD) (Noa® from Orthopnoea®).

The secondary objectives will be:
1. If the use of MAD modifies the strength of the genioglossus muscle measured by TDS and IOPI
2. If oropharyngeal exercises increase subjective parameters measured with Epworth, VAS and Pittsburgh questionnaires
3. If oropharyngeal exercises increase adherence to the use of MAD
4. If prior score obtained with TDS and IOPI can influence adherence or efficacy of MAD
5. If oropharyngeal exercises increase objective measures obtained with TDS and IOPI
6. If oropharyngeal exercises create any morbidity in patients with MAD (adverse effects)
Ethics approval(s)Approved 12/04/2023, Comite de Ética de Investigación de Malaga Hospital Regional Universitario (7ª planta Pabellón A, Avda. –Carlos Haya s/n, 29010, Málaga, Spain; +34 (0)951 29 1447 / +34 (0)951 29 1977; portaldeetica.csalud@juntadeandalucia.es), ref: 0324-N-23
Health condition(s) or problem(s) studiedSleep apnea
InterventionA myofunctional and anatomical evaluation of the patient diagnosed with obstructive sleep apnea/hypopnea syndrome (OSAHS) will be conducted in the same week as the polysomnography is performed. During this evaluation, patients are blindly examined by an otorhinolaryngologist and blindly allocated to each group.

Randomization will be simple randomization depending on the order the patient attends the Ear, Nose and Throat (ENT) consultation. The total duration of therapy will be 3 months. There will be four arms:
1. Sham therapy: expiratory exercises daily performed and written in a diary.
2. Myofunctional therapy: oropharyngeal exercises performed by an APP Airway Gym followed by telemedicine
3. Mandibular advancement device therapy: use of a titratable mandibular advancement device (NOA device)
4. Mandibular advancement device and oropharyngeal exercises: a combination of both

Subsequently, the muscle tone of the genioglossus muscle and the buccinator muscle are evaluated with IOPI, taking three measurements of each one and using the highest value. The tone of the tongue muscles is measured with the digital spoon, taking three measurements and using the highest one. Then is referred to the dentist to adapt MAD at the maximum distance allowed.

DISTRIBUTION OF HOSPITAL VISITS:
Visits during the study are distributed as follows:
SELECTION VISIT: The patient diagnosed with OSAHS at a pulmonology laboratory by means of an initial sleep study (with measurement of baseline AHI, night-time oxygen desaturation index and the lowest night-time oxygen saturation figures) is evaluated vis-à-vis the inclusion and exclusion criteria and then informed about the study. After reading the information and having any doubts solved, the patient accepts and signs the informed consent form in duplicate, taking one copy home.
ONE-OFF VISIT: The patient is evaluated by the otolaryngologist and fills in the sleepiness questionnaires, the TDS and IOPI. Exercises are explained and the group with MAD is referred to the dentist to provide the MAD.
FINAL VISIT: After 3 months there is another sleep study with anatomical measurements and questionnaires.
Intervention typeProcedure/Surgery
Primary outcome measureApnea-hypopnea index (AHI) measured by polysomnography/polygraphy measured on the first day and after 3 months
Secondary outcome measuresMeasured on the first day and after 3 months (except for sleep diary):
1. Oxygen desaturation index (ODI) measured by polygraphy/polysomnography
2. Minimal O2 desaturation (min sat o2) measured by polygraphy/polysomnography
3. Strength of the genioglossus muscle measured by Tongue Digital Spoon (TDS) and Iowa Oral Performance Instrument (IOPI)
4. Adherence to the use of MAD measured by sleep diary daily
5. Sleepiness measured with the Epworth sleepiness scale subjective scale
6. Subjective measure of snoring by partner using Visual Analogue Scale (VAS)
7. Quality of sleep measured with Pittsburgh questionnaires
8. Oropharynx dimensions measured with Friedman anatomical scales
Overall study start date01/01/2023
Completion date05/03/2026

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
Upper age limit75 Years
SexBoth
Target number of participants48
Key inclusion criteria1. Aged between 18 and 75 years
2. Diagnosis of moderate OSAHS (AHI between 15-30) without having had previous experience of said condition and not undergoing treatment due to different circumstances
3. Not having undergone any previous treatment for OSAHS
4. Signed informed consent (IC) form
Key exclusion criteria1. Cognitive or neurological deficit
2. Inability to answer questionnaires
3. Severe alcoholism
4. Presence of craniofacial malformations
5. Active neoplastic disease
6. History of prior orofacial muscle rehabilitation therapy and any prior apnoea treatment which may modify the study results (surgery, MAD, continuous positive airway pressure [CPAP])
7. Not having a smartphone
8. Temporomandibular joint dysfunction
9. Absence of dentition to wear a MAD
Date of first enrolment03/05/2023
Date of final enrolment05/12/2025

Locations

Countries of recruitment

  • Spain

Study participating centres

Hospital Quironsalud Marbella
Avda Severo Ochoa 20
Marbella
29603
Spain
Hospital Quironsalud Campo de Gibraltar
Edificio Arttysur.Avda de los Empresarios s/n 11379
Palmones, Cadiz
11370
Spain

Sponsor information

Quirons salud investigacion
Hospital/treatment centre

c/ Zurbaran 28
Madrid
28010
Spain

Phone +34 (0)917810682
Email qs.investigacion@quironsalud.es
Website https://www.quironsalud.es/es/investigacion

Funders

Funder type

Other

Investigator initiated and funded

No information available

Results and Publications

Intention to publish date03/06/2025
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal.
IPD sharing planThe datasets generated during and/or analysed during the current study are/will be available upon request from Dr Carlos O'Connor (carlos.oconnor@quironsalud.es). Data will be available on 01/01/2026. The type of data that will be shared: raw data. Consent will be obtained from all participants. Data will be collected anonymously.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Participant information sheet 17/04/2023 No Yes

Additional files

43496_PIS.pdf

Editorial Notes

09/05/2025: The following changes were made to the study record:
1. The recruitment end date was changed from 01/09/2024 to 05/12/2025.
2. The overall study end date was changed from 03/05/2025 to 05/03/2026.
17/04/2023: Trial's existence confirmed by the Comite de Ética de Investigación de Malaga.